Aprea Therapeutics Inc (APRE)
4.49
-0.01
(-0.22%)
USD |
NASDAQ |
Jun 10, 16:00
4.33
-0.16
(-3.56%)
After-Hours: 20:00
Aprea Therapeutics Cash from Financing (Quarterly): 14.71M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.71M |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 5.14M |
| December 31, 2022 | 0.0985M |
| September 30, 2022 | 0.5844M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 1.66M |
| September 30, 2021 | 0.087M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.1214M |
| March 31, 2020 | 0.0295M |
| December 31, 2019 | 91.20M |
| September 30, 2019 | -3.620M |
| June 30, 2019 | -0.4358M |
| March 31, 2019 | 5.433M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.620M
Minimum
Sep 2019
91.20M
Maximum
Dec 2019
5.479M
Average
--
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| Stoke Therapeutics Inc | 1.717M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
| iBio Inc | 5.025M |
| Theriva Biologics Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -3.936M |
| Cash from Investing (Quarterly) | -0.008M |
| Free Cash Flow | -13.24M |
| Free Cash Flow Per Share (Quarterly) | -0.9394 |
| Free Cash Flow Yield | -76.55% |